Frederick G. Vogt, Interim CEO and General Counsel of Iovance Biotherapeutics, Inc., filed a Form 4 on September 3, 2026, disclosing transactions in common stock and restricted stock units dated September 1, 2026.

Key Highlights

  • RSU vesting: 41,669 shares of common stock were acquired on September 1, 2026, upon vesting of restricted stock units at $0 cost.
  • Tax withholding: 17,702 shares were disposed of at $8.28 per share to satisfy mandatory tax withholding requirements upon RSU vesting; the filing states this was not an open market sale.
  • Remaining common stock: Following the transactions, Vogt directly beneficially owned 586,459 shares of common stock.
  • RSU balance: 83,338 restricted stock units remain outstanding from the March 1, 2024 grant, with remaining units vesting in equal quarterly installments.
  • Reporting person roles: Vogt is identified in the filing as both a Director and an Officer holding the title Interim CEO and General Counsel.

RSU Vesting and Share Withholding Details for Iovance Biotherapeutics Insider

According to the Form 4 filed with the SEC on September 3, 2026, Frederick G. Vogt reported two transactions in common stock of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), both dated September 1, 2026. The first transaction, coded "M," reflects the acquisition of 41,669 shares of common stock at $0 per share, representing shares underlying restricted stock units that vested on that date. Each RSU represents a contingent right to receive one share of the issuer's common stock, as noted in the filing's explanations.

The second transaction, coded "F," reflects the disposal of 17,702 shares at $8.28 per share. The filing explains that these shares were "withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs" and explicitly states this was "not an open market sale of securities." After both transactions, the filing reports Vogt held 586,459 shares of common stock directly, described as "common stock remaining after deducting the common stock withheld for taxes."

In Table II, the filing discloses that 41,669 RSUs were settled via the "M" transaction, leaving 83,338 RSUs outstanding. The filing notes this aggregate figure reflects only the remainder of RSUs granted on March 1, 2024, and does not include any other RSUs held by Vogt. The remaining RSUs are stated to vest in equal quarterly installments. The filing was signed by Frederick G. Vogt and dated September 3, 2026.

What Was Disclosed

The filing discloses an RSU vesting event on September 1, 2026, in which Vogt acquired 41,669 shares and had 17,702 shares withheld for taxes at $8.28 per share, leaving a direct beneficial ownership of 586,459 shares of common stock and 83,338 remaining RSUs.